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challenge. Nearly 20% of all mortality in industrialized coun-
tries is due to sudden cardiac arrest. This is of epidemic pro-
portion and remains a daunting problem. The actual
incidence of sudden cardiac death is highly variable but recent
prospective studies using multiple sources in the United
States, Europe, and China have estimated sudden death rates
ranging from 50 to 100 per one hundred thousand people in
the general population. Despite the reduction in overall cor-
onary heart disease mortality in the past thirty years, sudden
cardiac death has not declined to a similar extent suggesting
the percentage of deaths that are due to sudden cardiac arrest
has remained fixed or actually increased as a percent of the
total mortality. More than 50% of all coronary heart disease
deaths are caused by sudden cardiac arrest. The exact nature
of that sudden cardiac death has changed somewhat over the
past two decades. While a vast majority of sudden cardiac
arrest victims were felt to be due to ventricular tachycardia or
fibrillation two decades ago, recent data suggests the per-
centage of people dying of ventricular tachycardia/fibrillation
has decreased and incidence of sudden death associated with
bradyarrhythmias has increased. This is probably an expres-
sion of an aging population within an increasing incidence of
heart failure which demonstrates an inverse relationship to
the degree of heart failure with the incidence of sudden car-
diac death. Obviously death associated with end-stage heart
failure is not going to be mitigated by wide spread implanta-
tion of an implantable defibrillator.
The underlying cause of sudden cardiac death is very
complex. Sudden cardiac arrest increases with age, but at any
age the incidence is higher in men than women, until the
eighth decade where the incidences approach one another.* Division of Cardiovascular Medicine, Beth Israel Deaconess Medic
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sudden cardiac arrest has not really increased over time, just
the patients who are susceptible. Moreover, the incidence of
sudden death in older women does not appear to be related to
prior infarction, so the underlying substrate may be very
different. Despite the fact that coronary artery disease is
present in nearly three quarters of the patients with cardiac
arrest it is much lower in women of older age and thus the
mechanisms may be different. As such nearly two-thirds of
womenwho presentwith cardiac arrest have that event as the
first episode which is not the case in men where only about
40e50% presentwith sudden cardiac arrest as the first episode
of heart disease. This again suggests a different substrate. We
know that there are racial differences in the incidence of
sudden cardiac death. Hispanic Americans have a lower
incidence of sudden cardiac arrest than non-Hispanic in the
United States. African Americans have a higher incidence of
sudden cardiac death than white Americans. Survival rates
are lower for African American than non-African American
populations. Most sudden cardiac deaths occur in individuals
without a history of heart disease and importantly, with
relatively normal function and ejection fractions greater than
40%. Prediction of those patients at risk remains elusive. Most
of the efforts over the last 25 years have been focused on pa-
tients with abnormal ventricular function and congestive
heart failure, who are a minority of those who die suddenly.
There are many biological markers that have been looked at,
including incidence of coronary disease, coagulation factors,
renal function or hormonal status, family history, etc - none of
which are of specific value in individual patients. There are
known genetic risk factors for monogenetic primary
arrhythmic diseases, which make up a small percent of thoseal Center, 330 Brookline Avenue, Boston, MA 02215, USA.
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twenty population. The role of ion channel abnormalities in
the general population as a part of a complex underlying
substrate is yet to be determined. Clearly genome (GWAS)
studies have determined a number of potassium channel
defects that seem to be a high risk for certain populations, as
well as sodium channel defects. The markers which regulate
the nitrous oxide synthetase system (NOS1AP) have been
highly associated with sudden death. None of these genetic
markers in and of themselves can be a sole explanation for
such a complex disease. Numerous biological markers
including fatty acids, cytokines, CRP, BNP have all been related
to sudden cardiac death. A number of risk stratifiers have been
looked at, including autonomic dysfunction as measured by
heart rate turbulence, heart rate variability, and baroreceptor
responsiveness. Still other markers to assess alterations of
repolarization such as T-Wave alternans have been used.
Simple surrogate measures on an ECG including QRS width,
QRS notching, QT interval all have some small impact in our
understanding of the complex interrelationship of various
factors that culminate in sudden cardiac death. None of these
is currently useful in predicting outcome in any individual.
Obviously the QT interval used as a surrogate for potassium
channel defects as well as the NOS1APgene, which is highly
related tomodulation of long QT syndrome. Half of the genetic
variants noted in the GWAS studies have not been implicated
in potassium channel abnormalities or factors regulating
repolarization. Probably only a small portion of the QT varia-
tion is explained by the findings of GWAS studies. The QRS
abnormalities, which are another risk factor, also seem to be
associated with genetic abnormalities, but these are more
related sodium channel defects. It is likely that many poly-
morphisms in addition to previously unrecognized mutations
are responsible for defining the complex substrate causing
sudden death. As such we need better risk factors that have a
greater sensitivity and specificity to identify those patients
with near normal heart function who represent the major
group of people who die suddenly. Since the incidence of
sudden death is so low in these patients, the chance of false
positives is extremely high; thus intervening based on such
risk factors may be fraught with poor cost effective delivery ofcare and complication related to the delivery of that care. This
is particularly true if ICDs are the therapy chosen. Beta
blockers seem to be the only drugs that are efficacious in the
prevention of sudden death in virtually all populations. The
management of heart failure symptoms with ACE inhibitors,
beta blockers and aldosterone antagonists seems to improve
sudden death as it improves the survival of heart failure, but
not specifically sudden death. The initial studies suggesting
that eplerenone is useful in preventing sudden death were
limited by the fact that the drug worked to prevent sudden
cardiac death in a population that may have a high incidence
of hypokalemia which itself may have been responsible for
the sudden death.
As such the prevention of sudden cardiac death remains
a daunting challenge, which appears insurmountable
because of our inability to identify patients at risk. It is likely
over the next decade the use of genomics, proteomics, and
metabolomics may help identify patients at risk when
added to non-invasive tests which can demonstrate small
abnormalities of an intramyocardial conduction and repo-
larization and abnormalities of autonomic tone. It is likely
that the abnormalities of autonomic tone may be more
dealing with the triggers of an event while other factors,
such as conduction or underlying substrate problems, have
to do with the latent ability of that individual’s heart to
wind up in fibrillation in response to a trigger. This sup-
plement will address many of these problems. While no
definitive solution of sudden cardiac death will evolve from
this symposium, organization of the issues is the first step
in our understanding of the problem and the methods by
which identification of those at risk can be undertaken. The
purpose of this special supplement is really to give the
readers an overview on what the definitions, epidemiology,
and incidence of sudden cardiac death is and the methods
identifying those patients at risk. The role of ICDs and non-
ICD interventions will be discussed as well as the guidelines
for ICD implantation in clinical practice. The role of phar-
macology will be addressed as well. This symposium is just
the beginning. The next decade or more will hopefully yield
better information to select those patients in whom more
cost effective therapy can be easily applied.
